AI-Enabled Cyclic Peptide Discovery

Oral Cyclic Peptide Design & Development Services

Connect target insight, macrocycle discovery, oral developability and experimental evidence in one project-specific workflow.

Explore the Workflow →

Macrocyclic Peptide Services

From Target Insight to Testable Cyclic Peptide Candidates

Our services connect target and binding-interface assessment, cyclic peptide hit discovery, oral developability optimization, modality design, and experimental feedback. Each project starts from the evidence available—whether a target, a screening hit, or an established peptide scaffold—and defines the next decision before selecting computational and experimental work.

Explore the service groups below, or follow the IL-23R example to see how a target-focused oral macrocyclic peptide program can be structured. The example describes work we can scope with a client; it does not represent an internally generated IL-23R asset or clinical outcome.

01 / Discovery & Hit Finding

Library Design & Hit Finding

Assess the target surface and binding interface, define differentiating regions and design a focused or diverse macrocyclic peptide library for virtual prioritization and subsequent screening.

AI-Accelerated Cyclic Peptide Library Design & Customization

Target-informed library composition, scaffold diversity, virtual prioritization and selection of candidates for a focused discovery campaign.

Explore library design service →

PPI Inhibitor Design

Analyze protein–protein interfaces, plausible binding hotspots and selectivity questions to guide cyclic peptide concepts for extracellular or intracellular PPIs.

Explore PPI inhibitor design →

02 / Oral Design & Developability

Optimize Binding, Exposure and Buildability Together

Two valid entry points are redesigning an active peptide for oral exposure, or selecting a permeability- and stability-oriented scaffold before adding target-binding features. The appropriate path depends on starting evidence and the trade-offs measured in the project.

AI-Driven Oral Cyclic Peptide Design

Generate and compare sequences, stereochemistry and conformational constraints against activity and oral-property objectives.

Explore oral design →

Permeability & Drug-Likeness

Prioritize permeability-related features while distinguishing membrane or intestinal assay results from measured oral bioavailability.

Explore permeability assessment →

ADMET Prediction

Compare defined absorption, stability, distribution and clearance hypotheses with stated model applicability and a plan for empirical calibration.

Explore ADMET prediction →

Lead Optimization

Rank hit-to-lead modifications jointly for potency, selectivity, permeability, metabolic stability and synthesis risk.

Explore lead optimization →

Scaffold Hopping

Compare alternative cyclic frameworks around an existing hit while testing whether binding features and developability are retained.

Explore scaffold hopping →

Half-Life Extension & Albumin-Binding Design

Evaluate attachment sites and albumin-binding motifs against receptor activity, free fraction, exposure and route-of-administration goals. Scope the chemistry and PK evidence before offering a dedicated program.

Explore service →

03 / Targeting & Modality Design

Adapt the Macrocycle to the Biological Objective

Intracellular Target Engagement

Connect target-binding design with cellular entry and intracellular functional readouts where the target is inside the cell.

Explore intracellular targeting →

Peptide–Drug Conjugate Design

Consider peptide recognition elements, conjugation positions, linkers and payload-related constraints.

Explore PDC design →

Oral PDC Design

Assess an oral PDC concept case by case; conjugation does not itself establish oral feasibility.

Explore oral PDC design →

Cyclization & Synthetic Feasibility

Assess cyclization site, ring size, bicyclic topology, precursor sequence and chemistry-specific risks before committing to synthesis. A focused pilot and experimental feedback define the supported design space.

Explore service →

Experimental Validation

Plan structural confirmation and project-specific binding, function, permeability, stability or PK assays to answer defined candidate-selection questions.

Explore experimental validation →

Illustrative Project Workflow

What We Can Provide: An IL-23R Oral Macrocycle Workflow

Five-stage IL-23R oral cyclic peptide workflow: target and interface, scaffold discovery, oral optimization, optional half-life design, and experimental validation
Illustrative IL-23R workflow. Half-life design is included when exposure is limiting; experiments guide the next design round.

For a client exploring IL-23R antagonism, the following sequence links design choices to specific evidence. Stages can be commissioned together or separately, depending on available target data, known peptides and experimental capacity.

  1. 1. Target and binding-interface assessment

    Review IL-23R biology, structural information, ligand-binding surfaces and differentiation hypotheses; define the desired mechanism and selection criteria. See PPI inhibitor design.

  2. 2. Cyclic peptide scaffold discovery

    Build a target-informed virtual library, compare ring constraints and binding hypotheses, then nominate a focused screening set. Starting from a known peptide, compare alternative frameworks with scaffold hopping. See library design.

  3. 3. Oral-property optimization

    Iterate affinity and selectivity alongside conformational behavior, permeability-related properties, solubility and metabolic stability; rank candidates with uncertainty visible. See oral design, permeability, ADMET and lead optimization.

  4. 4. Half-life extension design, if exposure is limiting

    Compare attachment positions and albumin-binding concepts with receptor activity and oral-exposure objectives. This planned module requires a chemistry-specific feasibility review; longer systemic half-life alone does not demonstrate improved oral absorption.

  5. 5. Synthesis and experimental validation

    Review proposed cyclization topology and synthesis risk; produce a prioritized set for structural confirmation, IL-23R binding and functional tests, plus permeability, stability and PK work where scoped. Feed measured results into the next design round. See experimental validation.

IL-23R is used here as a public-domain example of a possible service workflow. Any study design, assay availability, deliverables and claims of performance require project-specific confirmation.

Start with Your Decision Point

Share a target, existing hit or peptide scaffold and the question your team needs to resolve. We can propose a focused combination of computational design and validation services.

Discuss a project →

Online Inquiry

Submit your project details below, and our team will respond within 24 hours.